secwatch.observer — SEC 8-K summary
======================================

Issuer:     Drugs Made In America Acquisition Corp. (DMAA)
CIK:        0002028614
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001213900-26-052324
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DMAA SPAC signs $1B deal to merge with AI/analytics firm Power Analytics Global
-------------------------------------------------------------------------------

- Definitive merger agreement with Power Analytics Global (PAGC) at target enterprise value of $1.0B; floor of $300M.
- Post-close ownership: ~90% to PAGC shareholders, ~10% to existing DMAA shareholders pre-PIPE dilution.
- Minimum cash target at closing of $30M (floor $15M) from trust account and/or PIPE financing.
- Merger subject to DMAA shareholder approval, SEC S-4 effectiveness, and Nasdaq listing of surviving entity.
- Two amendments on April 30, 2026 corrected governing law to Delaware and completed notice address provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2028614/000121390026052324/0001213900-26-052324-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2028614/000121390026052324/ea0289172-8k425_drugs.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-052324

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer